Moleculin preclinical data: Annamycin pancreatic cancer activity partly mediated by CD8+ T cells

Moleculin Biotech, Inc.

Preclinical data: Annamycin's pancreatic cancer activity is partially mediated by CD8+ T cells, suggesting an immune-mediated mechanism beyond direct cytotoxicity.
Data presented at AACR Conference on Pancreatic Cancer, Sept 25–28, 2026, at Hilton San Diego Bayfront; abstract published in Sept 15, 2026 Cancer Research supplement.
Presenter: Angela T. Alistar, MD (Morristown Medical Center, Atlantic Health System / Carol G. Simon Cancer Center); abstract title: 'Turning cold pancreatic tumors hot'.
Annamycin is not currently in clinical development for pancreatic cancer; lead program remains MIRACLE trial in relapsed/refractory AML, the basis of near-term milestones.
CEO Walter Klemp: data point to 'unexpected additional benefit'; if observation holds, it broadens where Annamycin might be useful and how it might be combined.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.